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Neuroinjury, including traumatic brain injury, ischemic and hemorrhagic stroke (intra-
cerebral  hemorrhage), subarachnoid hemorrhage and spinal cord injury, collectively is a
signiﬁcant biomedical problem worldwide. Yet there are few therapeutic options available.
We  submit that mass spectrometry-based proteomic approach can have a potentially high
impact  in biomarkers discovery and drug target identiﬁcation for various forms of CNS





proteomic application tools (differential, quantitative, and imaging mass spectrometry anal-
ysis) being used for translational neuroinjury research from animal studies to clinical studies
and validations.
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1.  Introduction
Acute traumatic and ischemic CNS injury is a signiﬁcant
biomedical problem without adequate therapeutic interven-
tions. It includes traumatic brain injury (TBI), ischemic stroke
and hemorrhagic stroke (or intracerebral hemorrhage (ICH)),
subarachnoid hemorrhage (SAH) and spinal cord injury (SCI).
Traumatic brain injury (TBI) is deﬁned as a neurotrauma
caused by a mechanical force that is applied to the head.
Annually in the United States, there is approximately 1.4–2.0
million incidents that involve TBI. Of these, nearly 100,000
patients die, another 500,000 are hospitalized, and thousands
of others suffer short and long term affect [1–3]. TBI is referred
to as a silent epidemic [4,5]. The Centers for Disease Control
and Prevention (CDC) report that approximately 5.3 million
Americans live with the effects of TBI, more  than Alzheimer’s
disease. Stroke is the second leading cause of death worldwide
and the third leading cause of death in the USA with an annual
incident of 750,000 [3,6]. An obstruction within a blood ves-
sel supplying blood to the brain (ischemic strokes) causes the
most common type of stroke, accounting for almost 80% of all
strokes. Other strokes are caused by bleeding in brain tissue
when a blood vessel bursts (hemorrhagic stroke) [7,8]. Simi-
larly, spinal cord injury (SCI) is considered among the most
frequent cause of mortality and morbidity in every medical
care system around the world. SCI is an injury resulting from
an insult inﬂicted on the spinal cord. It can lead to the loss
of sensory and motor function at the site of injury, so it is an
important cause of neurologic disability after trauma, such as
lifelong paralysis for SCI patients. The consequences of SCI
represent a major challenge for the life of the patient and
his family members [9,10]. The incidence of SCI in the United
States alone is estimated to be 11,000 new cases each year
affecting a total of 183,000–230,000 individuals [11].
Proteomic analysis is a useful technique for simultaneous
detection of multiple proteins in a biological system to explore
the relation among them under different conditions. It can be
deﬁned as the identiﬁcation, characterization and quantiﬁca-
tion of all proteins involved in protein expression patterns,
protein interactions, and protein pathways in the blood,
organelle, cell, tissue, organ or organism that can be studied to
provide accurate and comprehensive data about that system
[1,12]. Proteomics is a promising approach for biomarkers and
therapeutic target discovery, it can follow the disease-speciﬁc
proteins (type and concentration) at any given time in a pro-
teome and correlate these patterns with the healthy ones. It
has been used to study protein expressions at the molecular
level with a dynamic perspective that help to understand the
mechanisms of the disease [5,13]. More  than 2 million differ-
ent protein products have been estimated in human proteome
[3,6,14,15].
Mass spectrometry (MS) is the most important tool for
protein identiﬁcation and characterization in proteomics due
to the overall feasibility and sensitivity of analysis [9,10,16].
Electrospray ionization with tandem mass spectrometry (ESI-
MS/MS) is one of the approaches that is used for protein
identiﬁcation and sequence analysis because it is an excel-
lent and convenient method for online transfer of the eluent
from the liquid chromatography to the mass analyzer of a i c s 1 ( 2 0 1 3 ) 65–73
mass spectrometer [11,17,18]. Obtaining knowledge to identify
proteins associated with a particular physiological or patho-
logical state, has a great signiﬁcance in understanding disease
states and to develop new diagnostic and prognostic assays
[19,20]. Neuroproteomics include comparative analysis of pro-
tein expression in normal and diseased states to study the
dynamic properties associated with neuropeptide processing
in biological system of diseases [21].
This review will discuss several key neuroproteomic areas
that not only address CNS injury research but also will address
the translational potential from animal studies to clinical
practice. We will cover three major neuroproteomic platforms:
differential neuroproteomics, quantitative proteomics, and
imaging mass spectrometry (IMS) approach.
2.  Differential  neuroproteomic  approach
Differential proteomic approach is ideally suited to discover
protein biomarkers that might be differentially expressed
or altered by contrasting two or more  biological samples
(Fig. 1). The complexity, immense size, variability of the
neuroproteome, extensive protein–protein and protein–lipid
interactions, proteins in the CNS tissues are extraordinar-
ily resistant to isolation [10,22]. Therefore, high resolving
protein/peptide separation methods are essential for the
separation and identiﬁcation. The development of modern
separation techniques coupled online with accurate and high
resolving mass spectrometric tools have emerged as preferred
components for diagnostic, prognostic and therapeutic pro-
tein biomarkers discovery that expands the scope of protein
identiﬁcation, quantitation and characterization. Proteomics
has two major approaches. The bottom-up (or shotgun)
approach involves direct digestion of a biological sample
using a proteolytic enzyme (such as trypsin) that cleaves
at well-deﬁned sites to create a complex peptide mixture.
The digested samples can then be analyzed by liquid chro-
matography (single or multi-dimensional) prior to tandem
mass spectrometry (LC–MS/MS) [23]. The second approach is
top-down that involves separating intact proteins from com-
plex biological samples using separation techniques such as
liquid chromatography or 2-D gel electrophoresis (isoelecto-
focusing + SDS-gel electrophoresis – separation by relative
molecular weight) followed by differential expression analy-
sis using spectrum analysis or gel imaging platforms. This is
sometimes assisted by differential dye-labeling of two  sam-
ples (e.g. with Cy-3, Cy-5 dye) and equal amount of the labeled
samples are mixed and resolved by 2-D gel, creating a differ-
ential gel map  or differential gel electrophoresis (DIGE) where
differentially expressed proteins (up- or down-regulated pro-
teins) can be identiﬁed by ﬂuorescence scanning and band cut
out for protein identiﬁcation [24].
In order to reduce complexity of the biological sample sep-
aration, multidimensional LC can be used in two  or more
different types of sequential combinations to improve signif-
icantly the resolving power and results in large number of
proteins being identiﬁed [25]. One of the powerful multidi-
mensional separation methods in proteomics is ion-exchange
chromatography (IEC) in the ﬁrst dimension. Reversed-phase
liquid chromatography (RPLC) most often in the second






























serum samples in both adult and in pediatric TBI [29–31]
(Table 1).





Traumatic brain injury UCH-L1, SBDPs, MAP2,
synaptotagmin, CRMP-2, GFAP, MBP
Ischemic stroke CRMP-2; EMAP-II, thrombospondin-1,
GSTP1, PRDX1, PARK7, NDKA, NSF,
Rho-GDI alpha
Hemorrhagic GFAP, S100b, sRAGEFig. 1 – General workﬂow for differential mass spec
imension is due to its compatibility with the downstream
ass spectrometry (sample concentration, desalting prop-
rties, and used volatile solvents). IEC is very suitable for
he separation of proteins and peptides based on their dif-
erences on overall charges. IEC’s stationary phase is either
nion or cation exchanger, prepared by immobilization of pos-
tively or negatively charged functional groups on the surface
f chromatographic column, respectively. Proteins or pep-
ide separation occurs by linear change of the mobile-phase
omposition (salt concentration or pH) that decreases the
nteractions with the stationary phase and ﬁnally eluted [17].
For neuroproteomic studies, Gao et al. [26] have described
 method for the 2-D differential display of proteins of
nﬂicted vs. non inﬂicted pediatric TBI cerebrospinal ﬂuid
CSF) study. Also, Kobeissy et al. [27] have used a mixed
ation- and anion-exchange chromatography (CAX) and 1-
 sodium dodecyl sulfate polyacrylamide gel electrophoresis
SDS-PAGE) approach for differential protein separation, differ-
ntially expressed protein bands are excised and trypsinized
ollowed by nanoLC and ESI-MS/MS protein identiﬁcation.
ith this method, 59 proteins were identiﬁed as potential
iomarker candidates (Fig. 1). Protein marker candidates iden-
iﬁed include MAP-2, ubiquitin carboxy-terminal hydrolase-L1
UCH-L1), collapsin response element-2 (CRMP-2), synaptotag-
in  and alpha II-spectrin breakdown products UCH-L1 wasne of these proteins that was subsequently conﬁrmed to be
 good translational biomarker for TBI. Liu et al. [28] ﬁrst vali-
ated that UCH-L1 marker is not only differentially expressed
n rat brain tissue, but also in bioﬂuids following brain injury inetry-based translational neuroproteomic methods.
rodents. CSF is important here as it is proximal to the injured
organ, and thus likely to have these candidate markers in high
concentrations. Indeed that was the case for UCH-L1 – which
is elevated not only in the rat model of TBI (controlled corti-
cal impact; CCI) but also in the rat model of ischemic stroke
(using both quantitative immunblotting and sandwich ELISA
method) [28]. Secondly with the aid of the two antibody-based
sandwich ELISA, they were able to identify elevation of UCH-L1
in serum in both injury models as well. Subsequently,
UCH-L1 protein was found to be elevated in human CSF andstroke/intracerebral
hemorrhage
Spinal cord injury NF-L, GFAP, MBP, SBDP, UCH-L1,
RMP-2, Ywhaz, Itih4, Gpx3
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Others have also used 2-D separation followed by MS/MS
to identify candidate protein alterations for SCI [16,32–34]. For
example, Yan et al. identiﬁed 31 candidate proteins such as
heat shock protein (HSP-70 1B) elevated in day 1, spetin-7
is upregulated up to day 5 and 3-hydroxy-3-methylglutaryl-
CoA (HMGCoA) synthase 1 is down regulated in rat model
of SCI [32]. Similarly, Kang [33] used 2-D gel electrophore-
sis and matrix assisted laser desorption ionization time of
ﬂight mass spectrometry (MALDI-TOF MS)  and found 39 pro-
teins including neuroﬁlament L, annexin 5, heat shock protein,
tubulin beta, peripherin, glial ﬁbrillary acidic protein (GFAP),
peroxiredoxin 2, and apolipoprotein A are upregulated while
21 proteins showed reduction. Katano and colleagues further
found that collapsin response mediator protein-2 (CRMP-2)
in spinal nerves peripheral to dorsal root ganglia [35] is C-
terminally truncated following SCI, which is consistent with
what was also observed in TBI (rat model) and ischemic stroke
model [36,37]. Lubieniecka et al. using CSF samples from rat
model of moderate or severe SCI and quantitative LC-MS/MS;
identiﬁed 42 putative biomarkers of SCI, 10 of which represent
potential biomarkers of SCI severity [38]. Three of the candi-
date biomarkers (Ywhaz, Itih4, and Gpx3) were also further
validated by Western blot. This is important as it is highly
translational to human study (where the use of bioﬂuid rather
than brain tissue is far more  available and practical). We  also
recently performed biomarker analysis using CSF and serum
samples from both rat model of SCI and human cases of SCI
[39]. Promising markers include GFAP, myelin basic protein
(MBP), Alpha II-spectrin breakdown product (SBDP) and UCH-
L1 (Table 1).
For stoke research, both 2D-gel-MALDI and CAX-PAGE cou-
pled MS/MS  were used to identify differentially displayed
proteins in an animal model of ischemic stroke (middle cere-
bral artery occlusion – MCAO) [40,41]. Yao further identiﬁed by
immunblotting that one of the brain-cortex down-regulated
marker endothelial monocyte-activating polypeptide (EMAP)
II was indeed down-regulated in CSF and serum. Multiple
LC–MS/MS methods have also been attempted to study dif-
ferential plasma proteins in ischemic stroke [42]. Ning and
colleagues used similar tandem mass spectrometric method
to study degradomic cascade in plasma from 3 h to 3–5 days
after ischemic stroke, with or without t-PA treatment [43].
Ning et al. also used an interesting translational technique
by ﬁrst applying proteomic techniques to screen conditioned
media from human brain endothelial cultures subjected to
oxidative stress induced by nitric oxide [44]. Among 12
markers elevated after such stress, the high-ranking candi-
date thrombospondin-1 was tested in acute ischemic stroke
plasma samples, and they found that this protein was in
fact elevated within 8 h of stroke symptom onset by about
2-fold using enzyme-linked immunosorbent assay (ELISA).
Dayon, Sanchez and colleagues used an interesting clini-
cal technique with human brain extracellular ﬂuids (ECF)
(i.e. microdialysates) from acute stroke patients were inves-
tigated to assess the changes in protein levels associated with
ischemic damages using a shotgun proteomic approach based
on isobaric tagging and mass spectrometry [45]. Among 59 pro-
teins, two novel proteins: glutathione S-transferase P (GSTP1),
peroxiredoxin-1 (PRDX1) were found to be elevated in blood
samples from stroke patients [44,45]. The team of Sanchez i c s 1 ( 2 0 1 3 ) 65–73
used human postmortem CSF as a model of global brain insult
and identiﬁed two markers. PARK7 and nucleoside diphos-
phate kinase A (NDKA) that are subsequently validated to be
candidate plasma markers for stroke in CSF and in plasma [46].
Lastly, Cuadrado et al. analyzed the human brain proteome
following ischemic stroke and identiﬁed 39 proteins by 2D-gel
electrophoresis/MALDI-based proteomics. Among those that
are conﬁrmed by immunblotting in the brain parenchyma
are dihydropyrimidinase-related protein 2 (CRMP-2), vesicle-
fusing ATPase (N-ethylmaleimide-sensitive fusion protein;
NSF) and Rho GDP-dissociation inhibitor 1 (Rho-GDI alpha)
[47]. For potentially plasma markers that can differentiate
ischemic from hemorrhagic stroke: S100B plasma levels were
increased in intracerebral hemorrhage (ICH), whereas sRAGE
levels were decreased in ICH as compared to Ischemic stroke
thus S100B/RAGE pathway might be promising markers in this
regard [48] (Table 1).
3.  Quantitative  proteomic  approach
For clinical utility purposes, it is often important to not
only identify what marker is present in a clinical sample,
but how much of the candidate marker is present. This is
particularly important in bioﬂuid samples such as CSF and
serum/plasma. Sandwich ELISA is the most classic quantita-
tive detection method for proteins. However, it requires two
high afﬁnity antibodies that are compatible with each other
(non-competing) to the same target proteins, and the assay
constructed is compatible with the matrix environment with-
out high background. Alternatively, if a target protein can
be identiﬁed and quantiﬁed by a mass spectrometry-based
method, it can be a powerful approach. There are two  basic
approaches for quantiﬁcation: relative quantiﬁcation (sam-
ples are differentially labeled then, the peak intensity ratio
between heavy and light peptides is measured to compare pro-
tein abundance) and absolute quantiﬁcation (a known amount
of isotope-labeled standard is mixed with the analyte, the
absolute amount of the analyte is calculated from the ratio
of ion intensities).
3.1.  Relative  quantiﬁcation
Many labeling methods have been developed, including
chemical, isobaric, and metabolic labeling techniques. The
isotope-coded afﬁnity tags (ICAT) is a chemical labeling
method [49,50], in which the Cys residues in proteins is cou-
pled with a compound containing stable isotope (light and
heavy) that is used for labeling of different samples. Both sam-
ples are then combined and subjected to protease digestion
followed by afﬁnity-puriﬁcation of Cys-containing peptides.
Another in vitro labeling method is Isobaric tagging with a
molecular tag that has a distinct added mass. Isobaric tagging
is a clever chemical isotope incorporation method based on
tags with an identical chemical structure and same total mass
but with labile parts (reporter ions with distinct m/z) gener-
ated under collision-activated dissociation. The reporter ions
are characteristic of each tag form and detected at distinct
m/z. The tandem mass tags (TMT), isobaric tag for relative and
absolute quantitation (iTRAQ), and ExacTag are examples of


























tFig. 2 – General workﬂow for quantitative mass spec
uch technology. Often two or more  of such tags with slightly
ifferent mass tags are used to label two (or more)  samples to
chieve differential protein quantiﬁcation [51–53] (Fig. 2A). An
lternative labeling method is in vivo stable isotope-labeling
ethod that introduce the labeled isotope at the level of
rotein synthesis, where cells are cultivated in a medium sup-
lemented with an appropriate stable isotope labeled nutrient
o achieve labeling of whole proteome [54,55].
.2.  Absolute  quantiﬁcation
o achieve absolute quantiﬁcation, the ﬁrst assumption is
hat each protein will have one or more  strongly ionizable
nd unique peptides produced by a robust protease such as
rypsin (tryptic peptide). One can conﬁrm this by using puri-
ed protein digest, for example, if one peptide is selected,
oth non-labeled and heavy-isotope labeled peptides can be
ynthetically made. We can then use the multiple-reaction
onitoring mode (MRM)  to ﬁnd the ions that are distinct
o both of these peptides, this allows for the establishment
f standard curve for quantiﬁcation. The concept is to spike
n both labeled and unlabeled peptides and conﬁrm their
etectability and the sensitivity of detection in the biological
atrix (e.g. control or normal CSF or serum samples). Once
hat is established, diseased state or control samples are then
nalyzed using this method with the spiking the heavy iso-
ope peptide. Thus one would be able to simultaneously detectetry-based translational neuroproteomic methods.
the naturally occurring peptide in relation to the heavy iso-
tope labeled peptide. Since we have the absolute amount of
what was spiked in by comparing the area under the curve
of these two peptides, one could achieve absolute quantiﬁca-
tion. Ottens used this method to quantify a distinct peptide
in myelin basic protein (MBP) isoforms as well as a fragment
that is distinct in the MBP-breakdown product [12] in rat sam-
ples of injured cortex lysate and in CSF samples (Fig. 2B).
Similarly, using a distinct tryptic peptide GFAP is also iden-
tiﬁed as being released and quantiﬁed from rat mixed cortical
neuronal-glial cell culture challenged with glial toxins that
trigger necrosis (maitotoxin) and apoptosis (staurosporin),
respectively [56].
In serum or plasma samples when the target molecule
is likely to be in minute amounts to reduce the risk of ion
signal suppression by abundant proteins, an additional step
of signal enrichment can be performed. For example, we
can use a high afﬁnity antibody (such as a polyclonal anti-
body) either directly conjugated to agarose beads or magnetic
particles. This antibody-conjugate is then incubated with
the biosample. For immune-binding followed by sedimenta-
tion or immunoafﬁnity precipitation [57,58]. Such precipitate
can be washed extensively to remove other proteins, the
protein bound is ultimately released by acid denatura-
tion (e.g. 1 M glycine pH 2.3) and the released molecule is
subjected to tryptic digestion and MRM-based quantiﬁca-
tion.
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4.  Imaging  mass  spectrometry  (IMS)
approach
The central nervous system CNS is a high structural organ with
different anatomic regions for both the brain and the spinal
cord. Due to the molecular complexity of biological systems
there is a need for molecularly speciﬁc tools to study pro-
teomic distribution spatially and temporally. In the biomedical
and clinical areas, this is often achieved by imaging scans
(such as MRI, CT and PET scans). These techniques are used
to detect compounds with high concentrations and do not
provide an overview of the unknown compounds. The study
of protein distribution directly in tissue by IMS will allow us
to gain more  extensive view of the biological processes and
interactions. To study a certain neuroprotein or biomarker by
mass spectrometry, it is not only advantageous to identify
the presence of biomarkers but also to obtain 2D and even
3D localization (spatial information) in the tissue. The ﬁrst
applications of IMS  were by Caprioli and colleagues [59,60]. For
these analytes range in size from small molecules to peptides
and proteins (less than 30 kDa, generally) [61]. More recently,
identiﬁcation of proteins directly from tissue using in situ
tryptic digestion coupled with IMS  has also been reported
[62].
In IMS,  a 2-D image  is generated by rastering the tissue
section with a laser beam in an X, Y direction, collecting
data from thousands of points. Thus, each spot contains a
unique mass spectrum from the rastered point. The inten-
sity of each m/z value versus the X, Y position generates a 2-D
ion density map.  MSI  thus preserves the spatial distribution
of molecules within the tissue. Sample preparation in MSI is a
critical step for generating high quality data and images. The
surgically removed organ is ﬂash frozen by gentle submersion
in liquid nitrogen. Flash-frozen tissue can then be stored at
−80 ◦C for at least a year with little degradation [63]. Tissue
sectioning is performed in a cryostat chamber held between
−5 ◦C and −25 ◦C. The tissue is held on the mounting stage
by adding a few drops of HPLC grade water [64]. The low tem-
perature of the cryostat causes the water droplets to freeze
thus holding the tissue in place on the mounting stage. Use of
optimal cutting temperature polymer (OCT), used as embed-
ding medium while sectioning the tissue should be avoided,
as OCT has been reported to suppress analyte ion forma-
tion in MALDI-MS studies [63]. The frozen tissue is sliced into
thin sections (10–20 m thickness) and thaw-mounted on to
MALDI stainless steel plate or conductive glass slide. Anal-
ysis of proteins or peptides requires washing with organic
solvents prior to coating with the matrix. Washing removes
endogenous interfering biomolecules such as lipids and salts
thus improving signal quality [65]. Tissue samples are then
coated with organic compounds that act as matrix. Proper
selection of matrix is a critical step in MALDI to obtain good
quality spectra. The most commonly used MALDI matrices are
sinapinic acid (SA), -cyano-4-hydroxycinnamic acid (CHCA)
and 2,5-hydroxybenzoic acid (DHB). SA is used for analyz-
ing proteins with high molecular weight. CHCA and DHB are
used for small molecules like peptides and lipids. The role of
matrix in MALDI is to facilitate ablation and ionization of com-
pounds in the sample. Uniform coating of the tissue section i c s 1 ( 2 0 1 3 ) 65–73
with matrix is important for efﬁcient extraction and desorp-
tion of molecules from the tissue surface. Excessive matrix
can cause migration of analytes in the tissue section. Con-
versely, insufﬁcient or uneven deposition of matrix can lead
to unstable and poor analyte signal. The most common tech-
niques used for coating matrix are, pneumatic spraying [66],
inkjet printing [67], sublimation of matrix [68] and acoustic
matrix deposition [69] because they produce a homogenous
layer of small MALDI matrix crystals [70]. Several mass ana-
lyzers are used for IMS studies such as, linear ion traps (LIT),
orbitrap, QqTOF, and TOF/TOF instruments. TOF mass analyz-
ers have no theoretical upper mass limit since TOF measures
time required for an ion to travel from the ion source to the
detector.
Using this technique, It is possible to identify protein
biomarker – for example, a 12,959 Da protein implicated in
gentamicin-induced nephrotoxicity in rat was found to be
transthyretin (Ser(28)-Gln(146)) [71]. For neuroscience study, a
2-D-IMS-visualization of MBP in mouse brain, including well
deﬁned corpus callosum region where MBP  is highly localized.
For neuroproteomic study, IMS  was used to study 2-D visual-
ization of protein expression in mouse brain structures [72].
Fig. 3 shows general workﬂow for MALDI imaging. Coronal sec-
tions of rat brain were analyzed to study the distribution of
MBP. The image  shows distribution of 14 kDa  isoform of MBP
in the rat brain. It is also possible to combine brain IMS data
with classic histology staining [73] or with MRI [74]. In terms of
clinical translation, in principle, IMS can be applied to biopsy
and post-mortem brain tissue to examine protein localization
or alteration. IMS analysis protocol has recently been derived
for formalin-ﬁxed parafﬁn-embedded tissue often obtained as
clinical specimen [75].
5.  Selection  of  neuroproteomic  platform
With the different neuroproteomic techniques described here,
one should select a ﬁt-for-purpose method based on the
requirements of the particular neuro-injury study and sam-
ple type available. Differential proteomics approach is best
applied to neuro-tissue or cultured neural cell samples under
two or more  different experimental challenges. This approach
is very useful during the discovery phase of protein changes,
target or biomarker identiﬁcation. Quantitative proteomics
with molecular tag labels or metabolic labels are also use-
ful in differential protein analysis. Both tissue/cell sample
and CSF or culture media samples can be used. Label-free
quantitative proteomics method provides the most sensitive
detection. It works best if one already knows what the pro-
tein targets of interest are. This approach can then be used
to track brain injury-dependent and temporal or changes of
a one or more  protein targets. Due to its detection sensitiv-
ity, bioﬂuid samples including CSF, plasma and serum can be
used once the detection method is optimized. Lastly, imaging
mass spectrometry can be used to identify and/or quantify a
small number of protein markers in the brain following injury.
Its major advantage is that it can provide dimensional spatial
information and localization data that is absent with the other
proteomic methods. In general all three methods can be used
for both animal and human-based studies. However, imaging
t r a n s l a t i o n a l p r o t e o m i c s 1 ( 2 0 1 3 ) 65–73 71















rdapted from Mangaonkar, M.  Thesis, University of Florida:
roteomic perhaps presents the highest challenge for human
tudies since good quality brain tissue samples with minimal
ost-mortem delay will be most desirable.
.  Prospective/future  direction
n this paper, we review the various qualitative, comparative
nd quantitative mass spectrometry approaches that can be
sed in vitro and animal studies of CNS injury, but also their
ranslational aspects in clinical biosamples. As technological
dvances continue, a growth area is to explore the various
ost-translational modiﬁcations of speciﬁc brain protein suing
hese methods. Lastly, although we focused on CNS injury,
he principle we  discussed should apply to other neurological
onditions, diseases or disorders.
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